Harrow, Inc. 8.625% Senior Notes due 2026

Harrow, Inc. 8.625% Senior Notes due 2026

Compare this stock

HROWL Stock Report Card

$

VolatilityTechnicalsProfitPerformance

25%

Performance

Score:

10/100

HROWL returned -5.25% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

Score:

10/100

HROWL receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Profit

Score:

37/100

Out of the last 20 quarters, HROWL has had 5 profitable quarters and has increased their profits year over year on 5 of them.

Volatility

Score:

40/100

HROWL has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

Harrow, Inc. 8.625% Senior Notes due 2026 Summary

Nasdaq / HROWL
Healthcare
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.